4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.
4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial
Quick facts: 4D pharma plc
Price: 50.8363 GBX
Market Cap: £66.79 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE